Join Amgen for a national broadcast presentation on

Myth Busters: Exploring the Role of Aimovig

Wednesday, July 20, 2022
5:00 PM Eastern

Catherine B. Ham, MD
Assistant Clinical Professor, Department of Neurology
Director, VCU Health Headache Clinic

CONFIRM YOUR ATTENDANCE

Please RSVP to Amgen by:

RSVP Deadline: July 19, 2022

Maynard Orbeta, Amgen

Amgen Representative Program Host

(804) 514-2659
MORBETA@AMGEN.COM

INDICATION

Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Please see additional Important Safety Information on next page.

This event is by invite only. Please note approved audience is listed on next page.

IMPORTANT SAFETY INFORMATION

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see accompanying Aimovig® full Prescribing Information, including Patient Product Information.

This programs is intended for the following U.S. healthcare providers only: AN, ARNP, ALTMED, AUD, BN, BSN, CNA, CRP, CNS, CNSLR, NUTRNST, DMD, DDS, DNP, OD, DO, PharmD, PhD, DPM, HLTHADMIN, LDN, LPN, LVN, MS, MSN, MA, MD, ND, NRS, NM, NP, OPM, OSP, PHR, PHI, PHT, PHYTHERA, PA, PA-c, PSY, RD, RN, RPH, SW, TECH, VMD

This is not an independent medical education program and not eligible for credit toward continuing medical education requirements.

Notice: This event is conducted in accordance with the PhRMA Code on Interaction with Healthcare Professionals and is limited to invited healthcare professionals. Attendance by guests or spouse is not appropriate. Government employees are subject to state and federal laws and ethics rules that may limit your ability to receive any gifts, including meals, from pharmaceutical companies. If you are a state or federal employee, it is your responsibility to seek guidance and prior approval from your employer or site ethics counselor to attend this event.

State Laws: To comply with law and Amgen policies, Amgen is unable to offer food and beverages to (1) individuals with prescribing authority in Vermont or Minnesota; or (2) individuals employed by prescribers in Vermont who support the provision of healthcare. You have the opportunity to opt-out of the meal.

Disclosure by Amgen: Amgen reports payments and transfers of value made to healthcare professionals and other healthcare related entities in accordance with federal and state laws, regulations and other transparency obligations. Any items of value provided by Amgen at this event (including the provision of meals and refreshments) may be subject to public disclosure. If you have questions regarding this matter, please contact Amgen at 805-447-7422 or HCCSpendInquiry@amgen.com.

AMGEN®